LabCentral signs Science Exchange: outsourced services ‘increasingly important’

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/ChristianChan)
(Image: iStock/ChristianChan)
Cambridge-based LabCentral has signed on Science Exchange to provide its resident startups with access to outsourced services.

LabCentral is a shared laboratory workspace for life-sciences and biotech startups in Kendall Square.

With access to the Science Exchange​ marketplace, the startups will have access to more than 2,500 service providers that have been qualified through the ISO 9001-certified evaluation process.

The use of outsourced services is becoming increasingly important to life science and biotech companies large and small, and that’s true for our resident start-ups​,” Johannes Fruehauf, LabCentral co-founder and president told Outsourcing-Pharma.com.

Science Exchange has developed a unique ‘no-headache’ platform to streamline the process – making it easy to access services without having to negotiate each individual transaction​,” he added. “That was very attractive to us, since we’re all about removing barriers to help our companies meet their milestones faster and cost-effectively​.”

Science Exchange was certified under the EU-US Privacy Shield Framework​ in July of this year after completing a seven-step process to demonstrate compliance with various data protection requirements.

Also in July, the company partnered with IndieBio​ to provide the incubator with its services.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers